(77 days)
Not Found
Not Found
No
The device description and performance studies focus on a standard enzymatic assay and analyzer, with no mention of AI/ML techniques or data-driven learning processes.
No
The device is an in vitro diagnostic (IVD) system used for the quantitative determination of triglycerides, which aids in diagnosis and management of conditions, but it does not directly treat or prevent diseases.
Yes
The device is intended for the quantitative determination of triglycerides, and these results are "used for the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver diseases involving lipid metabolism, various endocrine disorders, or for assessing of the risk of developing cardiovascular diseases," which falls under the definition of a diagnostic device.
No
The device description explicitly states that the system includes a "Vitalab Selectra Analyzer," which is a piece of hardware used for quantitative analysis. The submission also describes reagents and a calibrator, which are physical components.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states the system is for the "quantitative determination of triglycerides in serum and plasma." This is a measurement performed on biological samples taken from the body.
- Purpose of Results: The intended use also states that the results "may be used for the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver diseases involving lipid metabolism, various endocrine disorders, or for assessing of the risk of developing cardiovascular diseases." This clearly indicates the results are used for medical purposes related to diagnosis and treatment.
- Device Description: The device description details how the system analyzes the sample (using a reagent and analyzer) to determine the concentration of triglycerides. This is a typical function of an in vitro diagnostic device.
- Sample Type: The device analyzes "serum and plasma," which are biological specimens.
All of these points align with the definition of an In Vitro Diagnostic device, which is a medical device intended for use in vitro for the examination of specimens derived from the human body solely or principally for the purpose of providing information concerning a physiological or pathological state, or concerning a congenital abnormality, or to determine the compatibility with potential recipients, or to monitor therapeutic measures.
N/A
Intended Use / Indications for Use
The Vitalab Triglycerides Reagent, the Vitalab Calibrator and the Vitalab Selectra Analyzer are intended for use as a system for the quantitative determination of triglycerides in serum and plasma. Triglycerides results may be used for the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver diseases involving lipid metabolism, various endocrine disorders, or for assessing of the risk of developing cardiovascular diseases.
Product codes (comma separated list FDA assigned to the subject device)
JIX; CDT
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The effectiveness of Vitalab Triglycerides Reagent on the Vitalab Selectra is shown in the following studies.
The recovery of triglycerides using the Vitalab Triglycerides Reagent is linear from 5 to at least 900 mg/dL, as shown by the The recovery of the span from 0 mg/dL to 930 mg/dL triglycerides. Regression statistics, which are forced through the origin, compare standard recoveries to dilution factors. These statistics are shown below.
sy.x = 3.7 mg/dL, (Vitalab Recoveries) = 1.164 x (Dilution Factor), n = 44
Precision is demonstrated by the replicate assay of commercially available control serum. Precision statistics, calculated analogous to the method described in NCCLS Guideline EP3-T, are shown below.
| Sample | n | mean | Within Run 1SD | Within Run %CV | Total 1SD | Total %CV |
|---|---|---|---|---|---|---|
| Serum 1 | 60 | 69 | 0.6 | 0.9% | 1.1 | 1.6% |
| Serum 2 | 60 | 291 | 1.6 | 0.6% | 4.4 | 1.5% |
| Serum 3 | 60 | 624 | 3.5 | 0.6% | 11.3 | 1.8% |
Fifty nine serum specimens ranging from 56 to 519 mg/dL triglycerides and 60 heparinized plasma specimens ranging from 28 to 701 mg/dL triglycerides were collected from adult patients and were assayed for triglycerides using the Vitalab Selectra Analyzer and another commercially available method. Results were compared by Deming regression and the following statistics were obtained.
Serum Correlation
Intercept -4.0 mg/dL (-6.9 to 1.16 mg/dL)
Slope 1.071 (1.059 to 1.083)
sy.x: 3.6 mg/dL
Plasma Correlation
Intercept -0.2 mg/dL (-2.4 to 2.1 mg/dL)
Slope 1.068 (1.057 to 1.079)
sy.x: 3.6 mg/dL
Where x = Competitive Reagent Results y = Selectra Results
The claimed detection limit is documented through the repetitive assay of normal saline. The mean and standard deviation of a 30 replicate within run precision study are both 0 mg/dL. The minimum detection limit, calculated as the mean plus two a so replations of the recovery values, is rounded up to 1 mg/dL, which is the round-off error of the assay.
The 14 day onboard reagent stability and 7 day calibration stability claims are documented through the assay of serum controls over the claimed periods. In all cases, the total imprecision of triglycerides recoveries over the test periods are less than 2 mg/dL.
The three day reconstituted stability claim for the calibrator is shown by assaying calibrators of increasing ages. The observed change in triglycerides concentration over three days was less than 5% and statistically insignificant.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1705 Triglyceride test system.
(a)
Identification. A triglyceride test system is a device intended to measure triglyceride (neutral fat) in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
0
Brea, CA 92821 T (714) 672-3553 F (714) 672-3554
Summary of 510(k) Safety and Effectiveness Information
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The Vitalab Triglycerides Reagent, the Vitalab Calibrator and the Vitalab Selectra Analyzer are used as a system for the quantitative analysis of triglycerides in serum and plasma. Triglycerides results may be used for the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction and other diseases involving lipid metabolism, various of patents will unders, or for assessing of the risk of developing cardiovascular diseases. The Vitalab Triglycerides Reagent determines triglycerides using the lipase/GPO enzymatic assay procedure coupled to a Trinder indicator reaction. The resulting increase in absorbance at 505 nm is proportional to the triglycerides concentration of the sample.
The Vitalab Triglycerides Reagent Kit and Vitalab Serum Calibrator are substantially equivalent to the Beckman Trighycerides Reagent Kit, product no. 445850 and the Synchron Multi-Calibrator, product no. 442600, which are marketed by Beckman Coulter, Inc. of Brea, CA.
The effectiveness of Vitalab Triglycerides Reagent on the Vitalab Selectra is shown in the following studies.
The recovery of triglycerides using the Vitalab Triglycerides Reagent is linear from 5 to at least 900 mg/dL, as shown by the The recovery of the span from 0 mg/dL to 930 mg/dL triglycerides. Regression statistics, which are forced through the origin, compare standard recoveries to dilution factors. These statistics are shown below.
sy.x = 3.7 mg/dL, (Vitalab Recoveries) = 1.164 x (Dilution Factor), n = 44
Precision is demonstrated by the replicate assay of commercially available control serum. Precision statistics, calculated analogous to the method described in NCCLS Guideline EP3-T, are shown below.
| Sample | n | mean | Within Run | Total | ||
|---|---|---|---|---|---|---|
| 1SD | %CV | 1SD | %CV | |||
| Serum 1 | 60 | 69 | 0.6 | 0.9% | 1.1 | 1.6% |
| Serum 2 | 60 | 291 | 1.6 | 0.6% | 4.4 | 1.5% |
| Serum 3 | 60 | 624 | 3.5 | 0.6% | 11.3 | 1.8% |
Fifty nine serum specimens ranging from 56 to 519 mg/dL trig!ycerides and 60 heparinized plasma specimens ranging from 28 to 701 mg/dL triglycerides were collected from adult patients and were assayed for triglycerides using the Vitalab Selectra Analyzer and another commercially available method. Results were compared by Deming regression and the following statistics were obtained.
| Serum Correlation | ||
|---|---|---|
| Intercept | -4.0 mg/dL | -6.9 to 1.16 mg/dL |
| Slope | 1.071 | 1.059 to 1.083 |
| sy.x: | 3.6 mg/dL | |
| Plasma Correlation | ||
| Intercept | -0.2 mg/dL | -2.4 to 2.1 mg/dL |
| Slope | 1.068 | 1.057 to 1.079 |
| sy.x: | 3.6 mg/dL | |
| Where | x = Competitive Reagent Results | |
| y = Selectra Results |
1
The claimed detection limit is documented through the repetitive assay of normal saline. The mean and standard deviation of a 30 replicate within run precision study are both 0 mg/dL. The minimum detection limit, calculated as the mean plus two a so replations of the recovery values, is rounded up to 1 mg/dL, which is the round-off error of the assay.
The 14 day onboard reagent stability and 7 day calibration stability claims are documented through the assay of serum controls over the claimed periods. In all cases, the total imprecision of triglycerides recoveries over the test periods are less than 2 mg/dL.
・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・
- 2017-01-11 11:1
11 11
The three day reconstituted stability claim for the calibrator is shown by assaying calibrators of increasing ages. The observed change in triglycerides concentration over three days was less than 5% and statistically insignificant.
Wynn Stocking Manager of Regulatory Affairs Clinical Data, Brea CA ... ...
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged in a circular pattern around the symbol. The caduceus is black, and the text is also black.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAR 1 0 2004
Clinical Data, Inc. c/o: Mr. Ned E. Devine, Jr. Entela, Inc. 3033 Madison Avenue, SE Grand Rapids, MI 49548
Re: K034000
Trade/Device Name: Vitalab Triglycerides Reagent and Vitalab Calibrator Regulation Number: 21 CFR 862.1150 Regulation Name: Calibrator Regulatory Class: Class II Product Code: JIX; CDT Dated: February 23, 2004 Received: February 24, 2004
Dear Mr. Devinc:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with-other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
3
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Jean M. Cooper MS, DVM.
Yean M. Cooper, MS, D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
510(k) Number (if known):
K03 4000
Device Name:
Vitalab Triglycerides Reagent and Vitalab Calibrator
Indications for Use:
The Vitalab Triglycerides Reagent, the Vitalab Calibrator and the Vitalab Selectra Analyzer are intended for use as a system for the quantitative determination of triglycerides in serum and plasma. Triglycerides results may be used for the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver diseases involving lipid metabolism, various endocrine disorders, or for assessing of the risk of developing cardiovascular diseases.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Alek S
Division Sign-Off
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K03 4000
OR
Over-The-Counter Use
(Optional Format 1-2-96)
Prescription Use
(Per 21 CFR 801.109)